<PAGE>


EXHIBIT 99.4

MIV Therapeutics' Coatings Presented at World Biomaterials Congress

June 22th, 2004 MIV Therapeutics Inc. (MIVT:OTCBB), is proud to announce that
it's proprietary, biocompatible Hydroxyapatite (HAp) ultra-thin coating
technology for passive and drug-eluting applications on cardiovascular stents
and other implantable medical devices was presented by MIVT at the 7th World
Biomaterials Congress in Sydney, Australia, May 17-21, 2004. World Biomaterials
Congress events are conducted every 4 years, and attract top scientists,
industry and medical professionals from around the World.

The MIVT was represented by Vice President of Coatings Dr. Tom Troczynski,
Ph.D., Professor of Ceramics at The University of British Columbia and by MIV's
V.P Operations, Arc Rajtar, MEng. Mr. Rajtar delivered an oral presentation
titled "Nanoporous Calcium Phosphate Thin Coatings for Stents" that focused on
cardiovascular applications of MIVT proprietary coating technologies. Dr.
Troczynski presented a scientific poster "Mesoporous Bioglass Films by Sol-Gel"
and delivered a presentation on "In-Situ Formation of Nano-dispersed
Hydroxyapatite in Poly (propylene Fumarate) Matrix".

Alan Lindsay, CEO of MIVT stated, "We were very impressed by the high level of
interest in our proprietary Hydroxyapatite coating technology from the
professional community at this year's World Biomaterials Congress. This was the
first time our biocompatible coating has been presented to a multinational
audience at such a prestigious World-class event. The unique properties of our
proprietary coating, when applied to the demanding environment of cardiovascular
stents, place our research at the leading edge of new generation coating
technologies. Our strategy is to continue to further expand evidence of our
technology's validity and continue to progress methodically towards successful
clinical application in our target markets."

Dr. Troczynski commented, "Our research and development now enters another
critical stage which is expected to result in a truly biocompatible coating with
flexible drug eluting properties potentially useful for numerous applications in
the world of medical devices and implants. We continue to remain extremely
optimistic about these possibilities which we believe will offer considerable
opportunity to the medical field and to our investors, in general."

Mr. Rajtar added," The advantageous properties of our coating and its compliance
with to a comprehensive range of biocompatibility studies highlight the strength
of our coating material and the technologies used in its application. The
presentations were delivered to an international symposium of scientists and
industry professionals specializing in the medical device and the health care
profession. The enthusiastic responses received following the presentations were
extremely encouraging and rewarding."

About MIV Therapeutics

MIV Therapeutics is developing a "next generation" line of advanced
biocompatible coatings for passive and drug-eluting application on
cardiovascular stents and other implantable medical devices. MIV's ultra-thin
coating has been designed to inhibit inflammatory response and restenosis. A
Collaborative Research Agreement (CRA) between MIVI and the University of
British Columbia received a research and development grant from the Natural
Sciences and Engineering Research Council of Canada (NSERC) in 2002 for the
development of HAp as a drug eluting coating, and achieved the milestones for
Phase I of the program by demonstrating the coating has excellent properties
suitable for drug encapsulation and drug eluting purposes. MIVT's manufacturing
facility meets the guidelines applicable to CE Mark, FDA and GMP requirements.
Please visit www.mivtherapeutics.com for more information.

<PAGE>

MIVT has developed a proprietary HAp stent coating in collaboration with UBC and
has protected these collaborative technologies by supporting three patent
applications applied by UBC. MIVT has the exclusive worldwide license from UBC
to use and sublicense the HAp coating technologies for the development,
manufacture and sale of coated stents and other implantable medical devices.
Hydroxyapatite is a well-known, biocompatible, porous material that makes up
bone mineral and the matrix of teeth. It is widely used as a bone substitute
material and for coating implantable fixation devices in orthopedic, dental and
other applications. MIVT's ultra-thin coating formulation is designed primarily
to protect surrounding tissue from the chemical interaction of metal stents.
Following the successful completion of the first stage of its research and
development program, focusing on porous coatings for drug-elution purposes with
financial support from the Natural Sciences and Engineering Research Council of
Canada) the Company has progressed to the next development stage, which is
expected to finalize the drug-eluting research and development program.

Investor Inquiries:
Dan Savino
Investor Relations, MIV Therapeutics Inc.
Ph: 1 800 221-5108 ex.16
Fax: 604 301-9546
Email: dsavino@mivi.ca


Product inquiries and business opportunities:
Arc Rajtar
arajtar@mivi.ca
(604) 301-9545 ext 22

Except for the historical information contained herein, the matters discussed in
this press release are forward-looking statements. Such statements are indicated
by words or phrases such as "believe", "will", "breakthrough", "significant",
"indicated", "feel", "revolutionary", "should", "ideal", "extremely" and
"excited". These statements are made under "Safe Harbor" provisions of the
Private Securities Litigation Reform Act of 1995. Actual results may differ
materially from those described in forward-looking statements and are subject to
risks and uncertainties. See the Company's filings with the Securities and
Exchange Commission including, without limitation, the Company's recent Form
10-K and Form 10-Qs, which identify specific factors that may cause actual
results or events to differ materially from those described in the
forward-looking statements. Copyright (C) 2004 MIV Therapeutics Inc. All rights
reserved.